预约演示
Chutes & Ladders—Pfizer exec out the door in R&D shake-up
高管变更
None
Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.
Pfizer shakes up R&D leadership in preparation of Seagen merger
Pfizer
Pfizer is preparing to close its $43 billion SeageSeagener, which is expected later this year or in early 2024. Part of that prep includes changes to the Big Pharma’s research leadership team. Chief Scientific Officer Mikael Dolsten, M.D., Ph.D., is slated to take on more responsibilities while the company says goodbye to Chief Development Officer William Pao, M.D., Ph.D., who just took on the role in February 2022.
Pfizern will expand his role to become chief scientific officer and president of R&D. While he had previously been responsible for all discovery and early-phase clinical development, he will now also “lead an end-to-end model across all of Pfizer’s other therapeutic areas,” according to the company.
Pfizer also plans to promote Chris Boshoff, M.D., Ph.D, to serve as chief oncology research and development officer. He previously oversaw clinical research and product development activities for Pfizer’s oncology portfolio. In his new rolePfizeroff will be in charge of integrating medicines from Seagen. Fierce Biotech
FibroGen CEO Enrique Conterno has resigned FibroGen post for “personal reasons,” according to a company release.
FibroGen27-year-run at Eli Lilly, Conterno joined Fibrogen in 2020, when hopes surrounding the company’s anemia drug roxadustat were high. During his time at Lilly, Conterno is credited with returning its diabetes business to the industry's top spot, with annual revenue hitting more than $10 billion.
FibroGen his road at FibroGen proved much rockier, with the AstraZeneca-partnered drug roxadustat suffering an FDA rejection, commercial disappointments and a clinical trial flop.
Editas snags Biogen vFibroGenOAstraZenecaroxadustat
EdiFibroGencine
Long-time BioBiogenteran Linda Burkly, Ph.D., has landed at Editas Medicine, where she will serve as EVP and chief scientific officer. Burkly will lead the genome editing company’s drug discovery team and pipeline activities.
Editas Medicineran ended a 37-year tenure last year after most recently leading neuroscience-focused research teams as VP and senior distinguished investigator. During her time at the big biotech, Burkly is credited with inventing a new anti-CD4 mAb that was developed into the HIV treatment Trogarzo and discovering new VLA-4/VCAM biology and uses of VLA-4 blockers including for Crohn’s disease, an indication of Tysabri. Release
> AstraZenBiogenMene Pangalos, Ph.D., is set to step down asEditas Medicinemaceuticals R&D early next year after 14 years with the Big Pharma. Sharon Barr, who has headed up R&D at AstraZeneca’s rare disease unit Alexion since 2013, is set to fill the post. Fierce Biotech
> BiBiogenherapeutics has snagged former Amgen leader David Raben, M.D., to serve as the biotech’s chief medical officer. At Amgen, Raben most recently served as VP of global product development and product general manager of oncology, aanti-CD4 mAbat held a leadership position at Genentech.TrogarzoVLA-4/VCAMCrohn’s diseaseTysabri
> AstraZenecaSenda Biosciences has chosen Igor Matushansky, M.D., Ph.D., to serve as the company’s chief medical officer. He most recently served as CMO and global head of R&D at HoAstraZenecaa, and has past experAlexiont Daiichi Sankyo and Novartis. Release
> Bicara Therapeuticsdonça, M.D., will joAmgen Immune as chief medical officer, taking thbiotech from Johannes Streffer, M.D.Amgen is leaving to pursue a new role outside the company. Previously, Mendonça has held roles at Bial and AbbVie. ReleaseGenentech
> Peter PowchSenda Biosciencesto join Vaxxinity as EVP and global scientific director starting Oct. 1. Before Vaxxinity, he served as SVP and head of clinical development for RegeHookipa PharmaDaiichi SankyoNovartis
> Teva Pharmaceutical Industries has tapped Angus Grant, Ph.D., to take on the role of EVP of business development starting Aug. 1. Most recently, Grant was the chief businessRegenerone at BeiGene, and has also served as CEO of the Dementia Discovery Fund and held various leadership positions at Celgene. Release
> Annexon Bioscienceshas chosen Cyrus Mozayeni, M.D., to serve as CEO after former leader Bertrand Damour decided to step down. MUnity Biotechnologyly co-founded and helmed Vedere Bio throTakeda Pharmaceuticalsis. REliaLilly
> Teva Pharmaceutical Industriesnder, Chair and CEO Patrick McEnany has told the board he plans to retire from his role as CEO by the end of this year. McEnany has led the company since itsBeiGeneion in 2002 and will continue to serDementian-executive chair of the board after his CEO position is Celgene Release
> Pheon Therapeuticshas exited stealth with $60 million and CEO and co-founder Andrew Phillips, Ph.D., at the helm. He’s joined by co-founder and Chief Operating Officer MicVedere BioPh.D.; VP, head of biNovartisd co-founder Rhamy Zeid, Ph.D.; VP, head of operations and co-founder John Athanosopoulos; and VP and head of discovery Joe Patel, Ph.D. All of the leaders have previously worked at C4 Therapeutics, among other companies. Release
> Catalyst Pharmaceuticaltus Obochi, Ph.D., will take up the role of chief business officer at cell therapy company Sernova. Obochi has held past roles at Pfizer and Baxter International, among others. Release
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。